Revenues

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

The following table presents a summary of total revenues (in thousands): 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Xyrem	$	256,039	$	307,333	$	772,957	$	977,065
Xywav	255,936		153,063		677,041		352,643
Total Oxybate	511,975		460,396		1,449,998		1,329,708
Epidiolex/Epidyolex1	196,218		160,378		529,400		269,859
Sativex1	3,220		6,097		12,104		8,058
Sunosi2	—		19,251		28,844		42,981
Total Neuroscience	711,413		646,122		2,020,346		1,650,606
Zepzelca	70,320		71,714		197,943		181,972
Rylaze	73,513		20,674		200,687		20,674
Vyxeos	30,067		34,688		97,714		99,296
Defitelio/defibrotide	49,452		57,705		153,637		155,420
Erwinaze/Erwinase	—		—		—		69,382
Total Oncology	223,352		184,781		649,981		526,744
Other	1,001		3,344		3,576		8,768
Product sales, net	935,766		834,247		2,673,903		2,186,118
Royalties and contract revenues	4,886		3,868		13,348		11,389
Total revenues	$	940,652	$	838,115	$	2,687,251	$	2,197,507

__________________________

1.Net product sales for Epidiolex/Epidyolex and Sativex are included from the acquisition of GW on May 5, 2021.

2.Net product sales for Sunosi U.S. are included until the date of divestment to Axsome of May 9, 2022.

The following table presents a summary of total revenues attributed to geographic sources (in thousands): 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
United States	$	867,835	$	757,227	$	2,466,758	$	1,996,419
Europe	60,024		70,730		181,831		164,540
All other	12,793		10,158		38,662		36,548
Total revenues	$	940,652	$	838,115	$	2,687,251	$	2,197,507

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
ESSDS	57	%	57	%	56	%	62	%
McKesson	10	%	11	%	11	%	12	%

Financing and payment

Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days.

Contract Liabilities - Deferred Revenue

The deferred revenue balance as of September 30, 2022 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements

granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $0.5 million and $1.6 million during the three and nine months ended September 30, 2022, respectively, relating to these upfront payments. The deferred revenue balances are being recognized over an average of four years representing the period over which we expect to perform our research and developments obligations under each agreement.

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the nine months ended September 30, 2022 (in thousands): 

	Contract Liabilities
Balance as of December 31, 2021	$	2,556
Amount recognized within royalties and contract revenues	(1,569)
Balance as of September 30, 2022	$	987